REPAY Announces Inducement Award Grant for Rick Watkin

ATLANTA--(BUSINESS WIRE)-- Repay Holdings Corporation (NASDAQ: RPAY) (“REPAY” or the “Company”), a leading provider of vertically-integrated payment solutions, today announced an inducement award grant to Rick Watkin in connection with the closing of REPAY’s acquisition of KUBRA Data Transfer, Ltd. (“KUBRA”). Mr. Watkin will serve as President, KUBRA.

REPAY agreed to grant Mr. Watkin 833,333 restricted stock units (“RSUs”) as a material inducement to his entering into employment with the Company effective upon the closing of the KUBRA acquisition. The award was approved by the Compensation Committee (the “Compensation Committee”) of REPAY’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The grant was made to Mr. Watkin on June 1, 2026, and the RSUs will vest in equal annual installments over a three-year period beginning on the grant date, subject to Mr. Watkin’s continued service through the applicable vesting dates. The award was granted outside of REPAY’s equity incentive plans and is subject to the terms and conditions of the award agreement covering the grant.

About REPAY

REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs. REPAY's proprietary, integrated payment technology platform reduces the complexity of electronic payments for clients, while enhancing the overall experience for consumers and businesses.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260603861306/en/

Investor Relations Contact for REPAY:
[email protected]

Media Relations Contact for REPAY:
Kristen Hoyman
[email protected]

Source: Repay Holdings Corporation

You May Also Be Interested In

• Repay (RPAY) PT Raised to $4.25 at UBS to Reflect Kubra Acquisition
• Virtus Convertible & Income Fund II Announces Quarterly Distribution: 5.500% Series A Cumulative Preferred Shares
• Taiho Oncology Announces New England Journal of Medicine Publication of First All-Oral Regimen in Newly Diagnosed Acute Myeloid Leukemia